2-<2-Octanoyloxy-aethoxy>-aethanol-(1) | 7735-27-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-<2-Octanoyloxy-aethoxy>-aethanol-(1)
• 英文别名: Diethylenglykolmonocaprilat；2-(2-Hydroxyethoxy)ethyl octanoate
• CAS: 7735-27-5
• 化学式: C₁₂H₂₄O₄
• 分子量: 232.32
• InChiKey: NDYHDTGNPTWQMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-<2-Octanoyloxy-aethoxy>-aethanol-(1) 、 5-氯戊酸 以79%的产率得到
  参考文献：
  名称：

  ZEJNALOV B. K.; GARIBOV F. I.; NASIROV A. B.; KERIMOV P. M.; BAJRAMOVA M.+, UCH. ZAP. AZERB. YH-T. CEP. XIM. N., 1977, HO 2, 20-23

  摘要：

  DOI：

文献信息

• Fat-soluble substituting agent for substituting dehydrating agent for producing tissue preparation
  申请人：Shino, Junko

  公开号：EP0653617A2

  公开（公告）日：1995-05-17

  A fat-soluble substituting agent for substituting a dehydrating agent for producing a tissue preparation, comprising at least one selected from the group consisting of esters of fatty acid and alcohol and having a total carbon number of 6 to 50, preferaby 6 to 30 and ethers of the same kind or a different kind of alcohols and having a total carbon number of 6 to 50, preferably 6 to 30. The tissue preparation is prepared by fixing a tissue piece, dehydration-substituting with a dehydrating agent, substituting for the dehydrating agent with the fat-soluble substituting agent, embedding with an embedding agent, followed by slicing and staining (dyeing). It is odorfree and harmless.

  一种用于替代脱水剂制备组织制剂的脂溶性替代剂，至少包含一种选自脂肪酸和醇的酯类，总碳原子数为 6 至 50，最好为 6 至 30，以及同类或异类醇的醚类，总碳原子数为 6 至 50，最好为 6 至 30。组织制剂的制备方法是：固定组织块，用脱水剂脱水-取代，用脂溶性取代剂取代脱水剂，用包埋剂包埋，然后切片和染色（染色）。它不含异味，对人体无害。
• Cancer drug and uses
  申请人：Health Clinics Limited

  公开号：US10188668B2

  公开（公告）日：2019-01-29

  A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.

  一种药物组合物，包含一种癌症治疗剂，该治疗剂能够抑制和/或降低癌细胞吸收和利用葡萄糖或其他能量源、脂质或细胞膜或细胞器的其他构件和/或胆固醇的能力。药物组合物可包含一种或多种癌症治疗剂，可单独或联合给药。
• Compositions and Methods for Treating Severe Pain
  申请人：Infirst Healthcare Limited

  公开号：US20160101077A1

  公开（公告）日：2016-04-14

  The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
• Cancer Drug and Uses
  申请人：Health Clinics Limited

  公开号：US20170189425A1

  公开（公告）日：2017-07-06

  A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.
• US9504664B2
  申请人：——

  公开号：US9504664B2

  公开（公告）日：2016-11-29